Evidentic • Therapeutic Indications • Non-Hodgkin's lymphoma
Non-Hodgkin’s lymphoma (also known as NHL, or sometimes just lymphoma) is a type of cancer that starts in the lymphatic system, in white blood cells called lymphocytes that are part of the body’s immune system. NHL is a term used for many different types of lymphoma, all of which share some of the same characteristics.
Showing all 9 results
ProductBatch | Antigen | Molecular Class | Drug Brand | Product Concentration | CoA | Quantity per vial | Storage Temperature | Expiry Date | Price | |
---|---|---|---|---|---|---|---|---|---|---|
CD20 |
Monoclonal Antibody |
MabThera® |
10 mg/mL |
– |
2 mg |
-80°C |
05/2018 |
217,00Â € |
||
CD20 |
Monoclonal Antibody |
MabThera® |
10 mg/mL |
– |
2 mg |
-80°C |
09/2018 |
217,00Â € |
||
CD20 |
Monoclonal Antibody |
MabThera® |
10 mg/mL |
– |
2 mg |
-80°C |
12/2018 |
217,00Â € |
||
CD20 |
Monoclonal Antibody |
MabThera® |
10 mg/mL |
– |
2 mg |
-80°C |
02/2019 |
217,00Â € |
||
CD20 |
Monoclonal Antibody |
MabThera® |
10 mg/mL |
– |
2 mg |
-80°C |
02/2019 |
217,00Â € |
||
CD20 |
Monoclonal Antibody |
MabThera® |
10 mg/mL |
– |
2 mg |
-80°C |
08/2019 |
217,00Â € |
||
CD20 |
Monoclonal Antibody |
MabThera® |
10 mg/mL |
– |
2 mg |
-80°C |
12/2019 |
217,00Â € |
||
CD20 |
Monoclonal Antibody |
MabThera® |
10 mg/mL |
– |
2 mg |
-80°C |
07/2021 |
250,00Â € |
||
CD20 |
Monoclonal Antibody |
MabThera® |
10 mg/mL |
yes |
2 mg |
2-8°C / -80°C |
02/2023 |
217,00Â € |
Let us know about your inquiry details and we’ll contact you shortly.